Janux Therapeutics, Inc. announced that, under its collaboration with Bristol Myers Squibb, it has officially nominated a development candidate drug.

This development triggered the $35 million milestone payment clause stipulated in the cooperation agreement. The nomination of this drug candidate marks a substantial breakthrough in the collaboration between both parties in the field of tumor immunotherapy. The fulfillment of this milestone payment will further support Janux Therapeutics in advancing the research and development of its innovative therapy pipeline.